CROI 2015 Program and Abstracts

Keyword Index

Exosomes; 366 Explant; 86LB, 968 Exposed seronegative; 290 External validity; 578 – F – Facility factors; 1072

Gift voucher intervention; 1102 Global; 38LB

Hepatitis D; 707 Hepatitis delta; 708LB Hepatocellular carcinoma; 150, 640, 643 Heritability; 291 Herpes simplex virus; 27 Herpes virus coinfection; 190

Global deficit score; 478 Glucose metabolism; 320 Glycolysis; 497 Glycosylation; 215, 350 gp120; 212

Heterogeneity; 11 Heterosexual; 1031 Heterosexual women; 978LB HEV; 709 HEV RNA; 709 High-dose rifampin; 95LB High Mobility Group Box 1; 722 High-grade anal intraepithelial neoplasia; 714 High-mannose glycan; 350 Highly exposed seronegative; 288 Histone acetylation; 407 Histone deacetylase inhibitor; 408, 410, 411 Histone methylation; 407 Histopathology; 464 HIV; 37, 56, 59, 79, 84, 86LB, 90, 107, 134, 136, 146, 160, 162, 170LB, 192, 207, 248, 256, 273, 282, 290, 296, 299LB, 301, 306, 316, 319, 323, 342, 353, 360, 371, 394, 403, 412, 432, 445, 452, 462, 463, 471, 482, 486, 493, 502, 505, 507, 512, 520, 537, 549, 557, 573, 575, 580, 599, 617, 623, 628, 629, 634, 635, 639, 646, 647, 707, 709, 713, 716, 722, 730, 731, 740, 743, 748, 753, 756, 757, 774, 775, 783, 798, 801, 805, 808, 809, 815, 831, 833, 842, 846, 867, 868, 890, 891, 893, 901, 903, 905, 906, 911, 927, 944, 945, 954, 958, 974, 992LB, 1002, 1010, 1014, 1017, 1026, 1029, 1032, 1034, 1038, 1040, 1049, 1050, 1052, 1055, 1057, 1074, 1081, 1082, 1096, 1098, 1103, 1104, 1113 • Adherence; 988 • Cancer risk; 725, 717, 718, 725 • Associated neurocognitive disorder; 62, 63, 446, 447, 454, 456, 472, 483, 489, 493, 501, 506 • Associated neurocognitive impairment; 444, 478 • Associated non-AIDS; 565 • Care; 103LB • Care cascade; 252, 632LB, 1003, 1111 • Care continuum; 665, 851, 854, 890, 973, 997, 1005, 1068, 1097 • Cluster; 598 • Coinfection; 819, 849

gp120 transgenic mouse; 481 gp41 cytoplasmic tail; 220, 503 gp41 mutants; 589 Griffithsin/carrageenan; 968

FACTS; 26LB Failure; 699 Falls; 786 False-negative; 635 False-recent rate; 625 Fc fusion; 350

Group O; 230 Growth; 879 GSK1265744; 554LB GSK2838232; 538 GSS; 117 Guidelines; 99, 974, 1079, 1081 Gut; 270 • Associated lymphoid tissue (GALT); 271, 299LB • Homing; 274

Female and male; 921 Female condom; 995 Female reproductive tract; 273 Female sex workers; 135, 851, 852, 861 Fetal; 882 Fetus; 898 Fever; 883 Fibrosis; 150, 299LB, 325, 639, 643, 656 Financial incentives; 29 Financing; 1114 First-line ART failure; 457 Fishing communities; 1039 Fixed-dose combination; 687, 688 Flow cytometry; 680 Flow-mediated dilatation; 757 Food insecurity; 546 Foxo1; 426

• Immunology; 271 • Metagenome; 260 • Microbiome; 262 • Microbiota; 138, 261, 264, 265

GWAS; 295 – H – HA; 210 HAART; 71, 315 Hair concentrations; 514 Half-life; 81 HAND; 440, 452, 453, 464, 468, 471, 474, 482, 487, 500, 502 Harm reduction; 1063 HBsAg seroconversion; 703 HBV; 700, 702 HCV; 146, 149, 636, 639, 642, 644, 646, 647, 652, 658, 668, 675, 690, 696, 699, 1010 • Antibody avidity; 673 • NS3; 697 • Sequence; 664 • Testing; 665, 667, 668 • Treatment; 670 HCV/HIV coinfection; 147, 522, 653, 691 HDACi; 109, 369, 405, 422 Health • Care reform; 1066 • Policy; 1119 • Systems strengthening; 159 • Care personnel; 1027 • Care providers; 658, 1083, 1095 Healthy aging; 484 Hearing loss; 829 Helicobacter pylori; 849 Hematopoietic stem cells; 433 Heme oxygenase-1; 501, 502 Hemophilia; 690 Hepatitis; 807 Hepatitis B; 662, 701 Hepatitis B virus; 638, 706 Hepatitis C; 15, 18, 150, 180, 181, 648, 649, 651, 653, 654, 660, 661, 662, 672, 676, 681, 684, 686, 694, 1029 • Treatment; 660 • Virus; 79, 145, 486, 638, 641, 650, 666, 673, 693

Fozivudine; 544 Fraction; 1038 Fracture; 141, 775, 777 Frailty; 783 FRAX; 141 Functional HIV cure; 401 Functionality; 995 Fungal burden; 835 Fungal infection; 843 Fusion inhibitors; 589 – G –

Gag; 276, 328, 539 GALT; 263, 547, 548 Gamma deltaT cell; 278 Gender; 581 Gene editing; 400, 401, 434 Gene expression; 405, 408, 802 Gene therapy; 365, 400, 401, 402, 403, 434 Gene transfer; 66

• Controllers; 333 • Counselling; 177 • Cure; 417 • Dementia; 453, 455 • Dementia scale; 459, 472 • Diagnosis; 1061

Generalizability; 578 Genetic diversity; 242 Genetic polymorphisms; 697 Genetic variant; 461 Genetics; 293, 295, 516 Genital; 855 Genital tract HIV RNA; 857 Genital tract sampling; 857 Genome; 256 Genome-wide association; 517 Genomics; 293 Geographic differences; 996 Germinal center; 49, 167, 326 GFR; 642 GHESKIO; 156 Genotype; 662, 664, 856 Gentian violet (GV); 844

• Diagnostic algorithm; 613 • Disease progression; 97 • DNA; 61, 429, 437, 480, 568 • DNA decay; 374, 375 • DNA reservoir; 58, 435, 491, 492 • Drug resistance; 116, 594, 601, 604, 606, 607, 907, 982, 983 • Encephalitis; 481

Keyword Index

• Entry; 39, 212 • Epidemic; 1045 • Eradication; 61, 108 • Exposed; 880 • Exposed infants; 889 • Exposed uninfected children; 876, 881 • Expression; 390, 106, 390 • Immunology; 295

• Virus incidence; 660 • Virus kinetics; 683 • Virus treatment; 659, 669 • Virus vaccine; 685

685

CROI 2015